OGT is the sole enzyme that catalyzes the addition of O-linked β-N-acetylglucosamine (O-GlcNAc) to serine and threonine residues on target proteins. It is a nutrient sensor that couples cellular glucose availability to post-translational modification and signaling[@ogtregulation].
Protein Structure
Domain Architecture
OGT has a characteristic two-domain structure:
Mermaid diagram (expand to render)
TPR (Tetratricopeptide Repeat) Domain
12-13 predicted TPR motifs (34 amino acids each)
Forms a superhelical structure creating a large interaction surface
Mediates protein-protein interactions and substrate specificity
Different TPR configurations contribute to different isoforms[@ogtsplicevariants]
Catalytic Domain
Located at the C-terminus
Contains the active site that binds UDP-GlcNAc
Catalytic tetrad: His-Asp-Asn-Asp residues
The overall fold resembles a distorted TIM-barrel[@ogtstructure]
OGT-L: Extended N-terminus may enable additional protein interactions
mOGT: Truncated variant with different substrate specificity; localizes to mitochondria via unique N-terminus[@ogtmitochondrial]
Enzymatic Activity
Catalytic Mechanism
OGT transfers a single GlcNAc from UDP-GlcNAc to serine/threonine hydroxyl groups:
UDP-GlcNAc binding — OGT binds UDP-GlcNAc in the active site (KD ~ 10 μM)
Substrate protein binding — TPR domain positions target serine/threonine
Catalysis — The catalytic tetrad facilitates glycosidic bond formation
Product release — UDP and O-GlcNAcylated protein are released
The enzyme is highly selective for the O-GlcNAc linkage — it does not act on complex N-linked or O-linked glycans[@ogtstructure].
Kinetic Properties
Km for UDP-GlcNAc: ~10-50 μM (varies with substrate)
kcat: ~1-5 s⁻¹
Optimal pH: 6.0-7.0
OGT shows "substrate-assisted" catalysis where UDP-GlcNAc participates in the transition state
Role in Neurodegeneration
Alzheimer's Disease
OGT is central to the O-GlcNAcylation deficit observed in AD:
Tau hyperphosphorylation: Reduced O-GlcNAcylation at Thr231, Ser396, Ser404 allows increased phosphorylation by GSK3-beta and CDK5[@ogttaumodification]
APP processing: O-GlcNAcylation of APP at Thr576 reduces β-secretase cleavage, decreasing Aβ production[@ogtlinkage]
Synaptic failure: Reduced O-GlcNAcylation of PSD-95 and AMPA receptor subunits impairs synaptic function[@ogtsynaptic]
Parkinson's Disease
OGT protects against α-synuclein pathology:
O-GlcNAcylation of α-synuclein at Ser87 reduces its aggregation
mOGT may be particularly important in dopaminergic neurons
OGT provides metabolic stress protection in neurons vulnerable to PD[@ogtneuroprotection]
Tauopathies (PSP, CBS)
In 4R-tauopathies:
Reduced O-GlcNAcylation of tau 4R isoforms
Brain hypometabolism may reduce HBP flux and UDP-GlcNAc availability
OGA inhibitors aim to compensate by blocking the removal of O-GlcNAc[@ogttauad]
Key Substrates in Neurodegeneration
Regulation of OGT Activity
Post-Translational Modifications
OGT itself is regulated by several mechanisms:
Phosphorylation: OGT is phosphorylated at multiple sites, modulating activity
O-GlcNAcylation: Auto-O-GlcNAcylation may regulate function
Proteolytic cleavage: May generate active fragments
Nutrient-Dependent Regulation
OGT activity is directly coupled to nutrient status:
Glutamine availability also influences UDP-GlcNAc production[@ogthexosamine]
Partner Proteins
OGA (MGEA5): The counter-enzyme — dynamic cycling determines net O-GlcNAcylation levels
PP1/PP2A: Protein phosphatases can dephosphorylate OGT
14-3-3 proteins: Bind OGT and may regulate its activity
Therapeutic Relevance
OGT as a Therapeutic Target
Enhancing O-GlcNAcylation through OGT activation is an alternative to OGA inhibition:
OGT activators would directly increase O-GlcNAc addition to tau and other substrates, potentially providing more precise control than OGA inhibition[@ogtlinkage].
OGT Inhibitors
OGT inhibitors are also of interest for cancer therapy (cancer cells depend on O-GlcNAcylation). Not relevant for neurodegeneration, but understanding OGT inhibitor biology informs the target's pharmacology.
[GSK3-beta Protein](/proteins/gsk3-beta) — Kinase that phosphorylates tau at sites O-GlcNAcylation blocks
References
[Lazarus MB, et al. Structural basis of OGT catalysis and substrate recognition (2012)](https://pubmed.ncbi.nlm.nih.gov/22244767/). Journal of Molecular Biology. 2012.
[Wang Z, et al. O-GlcNAcylation of tau by OGT reduces phosphorylation (2011)](https://pubmed.ncbi.nlm.nih.gov/21807009/). Nature Chemical Biology. 2011.
[Kreppel LK, et al. OGT gene produces multiple protein isoforms (2010)](https://pubmed.ncbi.nlm.nih.gov/20612398/). Journal of Biological Chemistry. 2010.
[Hanover JA, et al. OGT: a master regulator of cellular information processing (2012)](https://pubmed.ncbi.nlm.nih.gov/23118029/). FASEB Journal. 2012.
[Khalil R, et al. OGT regulates synaptic plasticity via O-GlcNAcylation of PSD-95 (2012)](https://pubmed.ncbi.nlm.nih.gov/22956840/). Journal of Neuroscience. 2012.
[Schwartz KR, et al. O-GlcNAc modification of tau and APP: therapeutic targets (2022)](https://pubmed.ncbi.nlm.nih.gov/35271452/). Journal of Alzheimer's Disease. 2022.
[Zhang Z, et al. OGT-mediated O-GlcNAcylation protects neurons against metabolic stress (2020)](https://pubmed.ncbi.nlm.nih.gov/32826862/). Cell Death & Disease. 2020.
[Civiccio L, et al. O-GlcNAcylation of mitochondrial proteins by OGT (2017)](https://pubmed.ncbi.nlm.nih.gov/28941972/). Free Radical Biology & Medicine. 2017.
[Knecht H, et al. O-GlcNAcylation of tau in Alzheimer's disease brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21935752/). Acta Neuropathologica. 2011.